Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boccia

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Gynecologic Oncology|July 27, 2021
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysisC Marchetti, A Rosati, F De Felice, et al.
Epilepsy & Behavior : E&B|January 19, 2010
Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in miceMariano G Blake, Mariano M Boccia, Angel M Carcaboso, et al.
Cancer Treatment Reviews|October 14, 2017
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should knowF De Felice, C Marchetti, S M Boccia, et al.
Critical Reviews in Oncology/Hematology|March 19, 2025
Management of early-stage ovarian cancer: Open questions and debated issuesV Salutari, E Giudice, E Rapisarda, et al.
Neurobiology of Aging|January 15, 2018
APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease modelsElena Anahi Bignante, Nicolás Eric Ponce, Florencia Heredia, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor responseC Marchetti, A Fagotti, R Fruscio, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Gynecologic Oncology|July 27, 2021
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysisC Marchetti, A Rosati, F De Felice, et al.
Epilepsy & Behavior : E&B|January 19, 2010
Novel long-term anticonvulsant treatment with gabapentin without causing memory impairment in miceMariano G Blake, Mariano M Boccia, Angel M Carcaboso, et al.
Cancer Treatment Reviews|October 14, 2017
Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should knowF De Felice, C Marchetti, S M Boccia, et al.
Critical Reviews in Oncology/Hematology|March 19, 2025
Management of early-stage ovarian cancer: Open questions and debated issuesV Salutari, E Giudice, E Rapisarda, et al.
Neurobiology of Aging|January 15, 2018
APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease modelsElena Anahi Bignante, Nicolás Eric Ponce, Florencia Heredia, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open|May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor responseC Marchetti, A Fagotti, R Fruscio, et al.
Pageof 7